Photoimmunotherapy
(PIT), developed by the National Cancer Institute, involves Cetuximab
sarotalocan sodium infusion followed by laser irradiation. PIT exerts specific
antitumor effects on a variety of carcinomas that express epidermal growth
factor receptors. PIT is a new cancer treatment option approved by Japan ahead of other
countries worldwide. As of 2022, PIT is indicated in “unresectable, locally
advanced, or locally recurrent head and neck cancer, with priority given to
standard treatments such as chemotherapy when available”. The
conventional treatment for unresectable locally advanced or locally recurrent
head and neck cancer is palliative. Whether photoimmunotherapy can be curative
for unresectable locally advanced head and neck cancers depends on the case.
Herein, we report a case of locally recurrent nasopharyngeal carcinoma, treated
with photoimmunotherapy via the nasal cavity, along with a literature review.
Preoperative simulation provided considerable information on device selection,
numbers of devices, and availability of working space. As a result, a complete
response was obtained following a cylindrical
diffuser puncture. Cases of local recurrence of nasopharyngeal carcinoma are
considered a good indication for PIT. However, since the follow-up period after
treatment was short in this case, we will continue to conduct strict follow-ups and
accumulate more cases.
References
[1]
Mitsunaga, M., Ogawa, M., Kosaka, N., Rosenblum, L.T., Choyke, P.L. and Kobayashi, H. (2011) Cancer Cell-Selective in Vivo near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules. Nat journal, 17, 1685-1691. https://doi.org/10.1038/nm.2554
[2]
Sato, K., Ando, K., Okuyama, S., Moriguchi, S., Ogura, T., Totoki, S., et al. (2018) Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy. ACS Central Science, 4, 1559-1569. https://doi.org/10.1021/acscentsci.8b00565
[3]
Nakajima, K., Takakura, H., Shimizu, Y. and Ogawa, M. (2018) Changes in Plasma Membrane Damage inducing Cell Death after Treatment with Near-Infrared Photoimmunotherapy. Cancer, 109, 2889-2896. https://doi.org/10.1111/cas.13713
[4]
Feldman, R., Gatalica, Z., Knezetic, J., Reddy, S., Nathan, C.A., Javadi, N., et al. (2016) Molecular Profiling of Head and Neck Squamous Cell Carcinoma. Head Neck, 38, E1625-E1638. https://doi.org/10.1002/hed.24290
[5]
Tahara, M., Okano, S., Enokida, T., Ueda, Y., Fujisawa, T., Shinozaki, T., et al. (2021) A Phase I, Single-Center, Open-Label Study of RM-1929 Photoimmunotherapy in Japanese Patients with Recurrent Head and Neck Squamous Cell Carcinoma. International Journal of Clinical Practice, 26, 1812-1821. https://doi.org/10.1007/s10147-021-01960-6
[6]
Tsang, R.K. and Wei, W.I. (2015) Salvage Surgery for Nasopharyngeal Cancer. The World Journal of Otorhinolaryngology—Head & Neck Surgery, 1, 34-43. https://doi.org/10.1016/j.wjorl.2015.09.006
[7]
Chan, J.Y., Tsang, R.K. and Wei, W.I. (2015) Morbidities after Maxillary Swing Nasopharyngectomy for Recurrent Nasopharyngeal Carcinoma. Head Neck, 37, 487-492. https://doi.org/10.1002/hed.23633
[8]
Lam, W.K.J. and Chan, J.Y.K. (2018) Recent Advances in the Management of Nasopharyngeal Carcinoma. F1000 Research Review. https://doi.org/10.12688/f1000research.15066.1
[9]
Chen, Y.P., Chan, A.T.C., Le, Q.T., Blanchard, P., Sun, Y. and Ma, J. (2019) Nasopharyngeal Carcinoma. Lancet, 394, 64-80. https://doi.org/10.1016/S0140-6736(19)30956-0
[10]
Mao, Y.P., Tang, L.L., Chen, L., Sun, Y., Qi, Z.Y., Zhou, G.Q., et al. (2016) Prognostic Factors and Failure Patterns in Non-Metastatic Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy. Chinese Journal of Cancer, 35, Article No. 103. https://doi.org/10.1186/s40880-016-0167-2
